The updated Medscheme specialised drug list for 2023 has been published

By Staff Writer

May 12, 2023

Reimbursement is still dependent on authorisation and benefit limits.

Some drugs included:
ANTIHEMORRHAGICS
Hemlibra

CARDIOVASCULAR SYSTEM
Volibris

DERMATOLOGICALS
Dupixent

ANTIVIRALS FOR SYSTEMIC USE
Epclusa

ANTINEOPLASTIC AGENTS
Blitzima and Ristova (Rituximab)
Plegridy

IMMUNOSUPPRESSANTS
Myelenea and Filengia (Fingolimod)
Unamity
Tremfya

DRUGS FOR OBSTRUCTIVE AIRWAY DISEASES
Xolair

Reference url

Recent Posts

robotic surgery approval
               

NICE Grants Conditional Robotic Surgery Approval to Enhance Patient Care and Address Health Inequities

🤖 Are you ready for the future of surgery?

The recent approval of 11 robotic surgery systems by NICE could improve patient care in the NHS, leading to faster recoveries and minimal invasiveness. With a focus on real-world evidence, this transformative step aims to improve health outcomes while addressing access and equity concerns.

Explore how this innovative approach will shape the landscape of surgical procedures in the coming years!

#SyenzaNews #HealthcareInnovation #MedicalDevices #MarketAccess

sugary drinks cancer risk
        

Sugary Drinks Cancer Risk: Women Face Higher Oral Cavity Cancer Threat

💡 Are sugary drinks putting your health at risk?

Recent research highlights a staggering link between sugary beverage consumption and an increased risk of oral cavity cancer in women. With those consuming just one sugary drink per week facing nearly five times higher odds of developing this cancer, it’s crucial to reevaluate our dietary choices and their health implications.

Jump into the findings and discover how this modifiable risk factor could reshape public health strategies and clinical practices.

#SyenzaNews #oncology #HealthTech #healthcarepolicy

CAB–LA cost-effectiveness
    

Cost-Effective HIV PrEP: CAB-LA Transforms Prevention

💡 Can CAB-LA revolutionize HIV prevention for underserved communities?

A new study confirms CAB-LA’s cost-effectiveness as HIV PrEP, preventing 4.5 more infections per 100 users than oral PrEP and saving $42,517 in healthcare costs. It significantly benefits African American/Black MSM and cisgender women, aligning with EHE goals.

Explore how CAB-LA reshapes HIV prevention! Read the full article.

#SyenzaNews #HealthEconomics #HealthcareInnovation #CostEffectiveness

When you partner with Syenza, it’s like a Nuclear Fusion.

Our expertise are combined with yours, and we contribute clinical expertise and advanced degrees in health policy, health economics, systems analysis, public finance, business, and project management. You’ll also feel our high-impact global and local perspectives with cultural intelligence.

SPEAK WITH US

CORRESPONDENCE ADDRESS

1950 W. Corporate Way, Suite 95478
Anaheim, CA 92801, USA

© 2025 Syenza™. All rights reserved.